Palvella Therapeutics, Inc. Files 8-K for Name Change
Ticker: PVLA · Form: 8-K · Filed: Sep 24, 2025 · CIK: 1583648
| Field | Detail |
|---|---|
| Company | Palvella Therapeutics, Inc. (PVLA) |
| Form Type | 8-K |
| Filed Date | Sep 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: name-change, corporate-action
TL;DR
PALVELLA THERAPEUTICS (formerly PIERIS PHARMACEUTICALS) filed an 8-K for a name change. No other material info.
AI Summary
On September 24, 2025, Palvella Therapeutics, Inc. (formerly Pieris Pharmaceuticals, Inc.) filed an 8-K report. The filing primarily serves as a notification of a name change and does not contain significant financial updates or material business events as of this date. The company was incorporated in Nevada.
Why It Matters
This filing indicates a corporate rebranding for Palvella Therapeutics, Inc., which was formerly known as Pieris Pharmaceuticals, Inc. Investors should note this change in identity.
Risk Assessment
Risk Level: low — The filing is a routine notification of a corporate name change and does not disclose any new financial risks or material adverse events.
Key Players & Entities
- PALVELLA THERAPEUTICS, INC. (company) — Registrant
- Pieris Pharmaceuticals, Inc. (company) — Former name
- September 24, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a change in the company's name from Pieris Pharmaceuticals, Inc. to Palvella Therapeutics, Inc.
When was the name change officially effective or reported?
The date of the earliest event reported is September 24, 2025.
What was the company's previous name?
The company's previous name was Pieris Pharmaceuticals, Inc.
In which state is Palvella Therapeutics, Inc. incorporated?
Palvella Therapeutics, Inc. is incorporated in Nevada.
Does this filing contain any financial statements or material business updates?
Based on the provided text, this filing is primarily for a name change and does not appear to contain new financial statements or material business updates.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-09-24 06:01:02
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share PVLA The Nasdaq
Filing Documents
- tm2526823d1_8k.htm (8-K) — 28KB
- tm2526823d1_ex99-1.htm (EX-99.1) — 14KB
- 0001104659-25-092681.txt ( ) — 251KB
- pvla-20250924.xsd (EX-101.SCH) — 3KB
- pvla-20250924_def.xml (EX-101.DEF) — 26KB
- pvla-20250924_lab.xml (EX-101.LAB) — 35KB
- pvla-20250924_pre.xml (EX-101.PRE) — 24KB
- tm2526823d1_8k_htm.xml (XML) — 5KB
01
Item 7.01 Regulation FD Disclosure. On September 24, 2025, Palvella Therapeutics, Inc. (the " Company ") issued a press release announcing the expansion of the Company's QTORIN 3.9% rapamycin anhydrous gel development program into Clinically Significant Angiokeratomas. A copy of the press release is furnished herewith as Exhibit 99.1, and incorporated herein by reference. The information furnished pursuant to Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Document 99.1 Press Release issued by Palvella Therapeutics, Inc. on September 24, 2025* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) *Furnished herewith
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PALVELLA THERAPEUTICS, INC. Date: September 24, 2025 By: /s/ Matthew Korenberg Matthew Korenberg Chief Financial Officer